Investigating how glioblastoma cells adapt to stress caused by EGFR signaling.
EGFR signaling network adaptations to overcome RAS-induced membrane stress in glioblastoma
This study is looking at how glioblastoma cells handle stress from a specific signaling issue, which might lead to a new way these cells die, and it aims to find new treatment options for people with this type of brain cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11161932 on NIH RePORTER |
What this research studies
This research focuses on understanding how glioblastoma cells respond to stress induced by overactive EGFR signaling, which can lead to a unique form of cell death known as methuosis. By studying the cytoskeletal dynamics and structure, the researchers aim to uncover how these cancer cells cope with the stress and process macropinosomes, which are cellular structures involved in nutrient uptake. The approach involves using inhibitors to disrupt cellular networks and observing the effects on cell survival and behavior. This could lead to identifying new therapeutic targets for glioblastoma treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who may benefit from novel therapeutic approaches.
Not a fit: Patients with other types of cancer or those who do not have glioblastoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for glioblastoma that target the unique vulnerabilities of cancer cells under stress.
How similar studies have performed: While the specific approach of studying methuosis in glioblastoma is relatively novel, similar research has shown promise in understanding cancer cell adaptations to stress.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Lazzara, Matthew J — University of Virginia
- Study coordinator: Lazzara, Matthew J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.